A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old

Memorias do Instituto Oswaldo Cruz

Volumn 110, Issue 6, 2015, Pages 771-780

  Camacho, Luiz Antonio Bastos ^b   Freire, Marcos da Silva ^b   Leal, Maria da Luz Fernandes ^b   Maia, Maria de Lourdes de Sousa ^b   Martins, Reinaldo Menezes ^b   Sato, Helena Keico ^d   Fernandes, Guilherme Côrtes ^e   de Castro, Ivone Perez ^d   Ribeiro, José Geraldo Leite ^d   Lemos, Jandira Campos ^d   de Barros, Eugenio Oliveira Martins ^d   Yoshida, Anna Maia Yamamoto ^c   Igushi, Takumi ^b   Leitão, Márcia Borges ^d   Batista, Maristela ^d   Barros, Maria da Conceição ^d   Emilia, Nakamatsu ^d   Paganini, Elisabete ^d   Nascimento, Marileide ^b   da Silva, Nilce ^b   Pereira, Sirlene de Fátima ^f   Renoiner, Ernesto Isaac Montenegro ^f   Rocha, Marilia Ferraro ^d   Galdino, Marly Almeida ^d   Barbosa, Luiza de Marilac Meireles ^g   Costa, Zouraide Guerra Antunes ^f   more..

^a Instituto de Technologia em Imunobiologicos   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c The Laboratory at Bio Manguinhos   (Brazil)

^d Fiocruz ^*  (Brazil)

^e Santa Casa de Misericordia de Goiania   (Brazil)

^f MINISTÉRIO DA SAÚDE   (Brazil)

^g UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Immunogenicity; Randomised clinical trial; Yellow fever vaccine

Indexed keywords

ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

CAUSALITY; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; HEMOLYTIC PLAQUE ASSAY; HOARSENESS; HUMAN; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEIZURES; SEROCONVERSION; TREATMENT OUTCOME; VOMITING; YELLOW FEVER; YELLOW FEVER VIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CAUSALITY; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; FEVER; HEMOLYTIC PLAQUE TECHNIQUE; HOARSENESS; HUMANS; INFANT; MALE; SEIZURES; SEROCONVERSION; TREATMENT OUTCOME; VOMITING; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 85000608547     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-02760150176     Document Type: Article

References (40)

1. Adu FD, Omotade OO, Oyedele OI, Ikusika O, Odemuyiwa SO, Onoja AL 1996. Field trial of combined yellow fever and measles vaccines among children in Nigeria. East Afr Med J 73: 579-582.
2. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon MA, Burans JP, Olson JG, Bedford P, Kitchener S, Monath TP 2005. Randomized, double-blind, Phase III, pivotal field trial of the comparative immunogenicity, safety and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 72: 189-197.
3. Camacho LAB, Freire MS, Leal MLF, Aguiar SG, Nascimento JP, Igushi T, Lozana JA, Farias RHG 2004. Collaborative Group for the Study of Yellow Fever Vaccines. Immunogenicity of WHO- 17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 38: 671-678.
4. Collaborative Group for Studies with Yellow Fever 2007. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. Vaccine 25: 3118-3123.
5. Fleiss JL 1986. The design and analysis of clinical experiments, John Wiley & Sons, New York, 432
6. Georges AJ, Tible F, Meunier DMY, Gonzalez JP, Beraud AM, Sissoko- Dybdahl NR, Abdul-Wahid S, Fritzell B, Girard M, Georges- Courbot MC 1985. Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine. Vaccine 3: 313-315.
7. Gotuzzo E, Yactayo S, Córdova E 2013. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 89: 434-444.
8. Greenberg DP, Vadheim CM, Partridge S, Chang SJ, Chiu CY, Ward JI 1994. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group. J Infect Dis 170: 76-81.
9. Grupo Colaborativo do Programa Nacional de Imunizações para o Estudo da Soroconversão pela Vacina contra Febre Amarela 2003. Estudo multicêntrico de soroconversão pela vacina contra febre amarela. Cien Saude Colet 8 (2): 511.
10. Lhuillier M, Mazzariol MJ, Zadi S, Le Cam N, Bentejac MC, Adamowicz L, Marie FN, Fritzell B 1989. Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand 17: 9-15.
11. Martins RM, Homma A 2014. Há necessidade de doses de reforço para a vacina febre amarela? In G Levi, HIG Giamberardino, R Kfouri, Controvérsias em imunizações, Segmento Farma, São Paulo, p. 19-31.
12. Martins RM, Maia MLS, Farias RH, Camacho LAB, Freire MS, Galler R, Yamamura AM, Almeida LF, Lima SM, Nogueira RM, Sá GR, Hokama DA, de Carvalho R, Freire RA, Pereira Filho E, Leal MLF, Homma A 2013. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother 9: 879-888.
13. Meyer HM, Hostetler DD, Bernheim BC, Rogers NG, Lambin P, Chassary A, Labusquitre R, Smadel JE 1964. Response of Volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines. Bull World Health Organ 30: 783-794.
14. Michel R, Berger F, Ravelonarivo J, Dussart P, Dia M, Nacher M, Rogier S, Moua D, Sarr FD, Diop OM, Sall AA, Baril L 2015. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines? Vaccine 33: 2301-2306.
15. Monath TP, Gershman M, Staples JE, Barrett ADT 2013. Yellow fever vaccine. In SA Plotkin, WA Orenstein, PA Offit (ed.), Vaccines, 6th ed., Elsevier Saunders Inc, Philadelphia, p. 870-968.
16. Mouchon D, Pignon D, Vicens R, Tu-Ha-Thanh, Tekaia F, Teulières L, Garrigue G 1990. Étude de lavaccination combinée rougeolefièvre jaune chez l’enfant africain âgé de 6 à 10 mois. Bull Soc Pathol Exot 83: 537-551.
17. MS/FNS/PNI - Ministério da Saúde/Fundação Nacional de Saúde/ Programa Nacional de Imunizações 2001. Manual de procedimentos para vacinação. Available from: dtr2001.saude.gov.br/ svs/pub/MPV/mpv00.htm.
18. MS/SVS - Ministério da Saúde/Secretaria de Vigilância em Saúde Brasil 2014. Guia de vigilância em saúde. Available from: portalsaude.
19. saude.gov.br/images/pdf/2014/novembro/27/guia-vigilancia- saude-linkado-27-11-14.pdf
20. MS/SVS/DVDT/CGPNI - Ministério da Saúde/Secretaria de Vigilância em Saúde/Departamento de Vigilância das Doenças Transmissíveis/ Coordenação Geral do Programa Nacional de Imunizações Brasil 2014. Nota Informativa 143/CGPNI/DEVIT/SVS/ MS. Recomendações da vacinação contra febre amarela, após a declaração da Organização Mundial da Saúde. Available from: sbmt.org.br/portal/wp-content/uploads/2015/02/Nota-Informativa- 143-2014-Febre-Amarela.pdf.
21. Nascimento-Silva JR, Camacho LAB, Siqueira MM, Freire MS, Castro YP, Maia MLS, Yamamura AMY, Martins RM, Leal MLF, Collaborative Group for the Study of Yellow Fever Vaccines 2011. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 29: 6327-6334.
22. NIBSC - National Institute for Biological Standards and Control 2011. WHO reference reagent. The 1st International Reference Preparation For Anti-Yellow Fever Serum Monkey. NIBSC code: YF. Available from: nibsc.ac.uk/documents/ifu/YF.pdf.
23. Niedrig M, Lademann M, Emmerich P, Lafrenz M 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4: 867-871.
24. Niewiesk S 2014. Maternal antibodies: clinical significance, mechanism of interference with immune responses and possible vaccination strategies. Front Immunol 5: 446.
25. OPS - Organização Panamericana de Saúde 2005. Boas práticas clínicas. Documento das Américas. Available from: anvisa.gov.br/medicamentos/pesquisa/boaspraticas_americas.pdf.
26. Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA, Odoom JK, Nkrumah FK 2001. Antibody response to 17D yellow fever vaccine in Ghanaian infants. Bull World Health Organ 79: 1056-1059.
27. Pfister M, Kürsteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, L’age- Stehr J, Kaufhold A, Herzog C 2005. Immunogenicity and safety of Berna-YF compared with two other 17D yellow fever vaccines in a Phase 3 clinical trial. Am J Trop Med Hyg 72: 339-346.
28. Pichichero ME 1990. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a meta analysis. J Infect Dis 162: 753-755.
29. Ruben FL, Smith EA, Foster SO, Casey HL, Pifer JM, Wallace RB, Atta AI, Jones WL, Arnold RB, Teller BE, Shaikh ZQ, Lourie B, Eddins DL, Doko SM, Foege WH 1973. Simultaneous administration of smallpox, measles, yellow fever and diphtheria-pertussis- tetanus antigens to Nigerian children. Bull World Health Organ 48: 175-181.
30. Siegrist CA 2013. Vaccine immunology. In SA Plotkin, WA Orenstein, PA Offit (eds.), Vaccines, 6th ed., Elsevier Saunders Inc, Philadelphia, p. 14-32.
31. Soula G, Sylla A, Pichard E, Kodio B, Bentejac MC, Teulières L, Saliou P 1991. Étude d’un nouveau vaccin combiné contre la fièvre jaune et la rougeole chez des enfants agés de 6 a 24 mois au Mali. Bull Soc Pathol Exot 84: 885-897.
32. Staples JE, Bocchini Jr JA, Rubin L, Fischer M 2015. Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 64: 647-650.
33. Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, Yamamura AMY, Vasconcelos PFC, Oselka GW, Weckx LW, Salgado MF, Noale LFO, Souza VAUF 1999. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 17: 1042-1046.
34. Suzano CES, Amaral E, Sato HK, Papaiordanou PM 2006. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24: 1421-1426.
35. Vasconcelos PFC 2003. Febre amarela (yellow fever). Rev Soc Bras Med Trop 36: 275-293.
36. WHO - World Health Organization 1998. WHO Expert Committee on Biological Standardization. Available from:whqlibdoc.who.int/ trs/WHO_TRS_872.pdf.
37. WHO - World Health Organization 2005. International health regulations. Available from: who.int/ihr/9789241596664/en/index.html.
38. WHO - World Health Organization 2013a. Vaccines and vaccination against yellow fever. Wky Epidemiol Rec 88: 269-284.
39. WHO - World Health Organization 2013b. Causality assessment of adverse event following immunization (AEFI). User manual for the revised WHO classification. Available from: who.int/vaccine_ safety/publications/aevi_manual.pdf?ua=1.
40. Yvonnet B, Coursaget P, Deubel V, Diop-Mar I, Digoutte JP, Chiron JP 1986. Simultaneous administration of hepatitis B and yellow fever vaccines. J Med Virol 19: 307-311.